Literature DB >> 18774343

TRPV1 receptor in expression of opioid-induced hyperalgesia.

Anna Vardanyan1, Ruizhong Wang, Todd W Vanderah, Michael H Ossipov, Josephine Lai, Frank Porreca, Tamara King.   

Abstract

UNLABELLED: Opiates are currently the mainstay for treatment of moderate to severe pain. However, prolonged administration of opiates has been reported to elicit hyperalgesia in animals, and examples of opiate-induced hyperalgesia have been reported in humans as well. Despite the potential clinical significance of such opiate-induced actions, the mechanisms of opiate-induced hypersensitivity remain unknown. The transient receptor potential vanilloid1 (TRPV1) receptor, a molecular sensor of noxious heat, acts as an integrator of multiple forms of noxious stimuli and plays an important role in the development of inflammation-induced hyperalgesia. Because animals treated with opiates show thermal hyperalgesia, we examined the possible role of TRPV1 receptors in the development of morphine-induced hyperalgesia using TRPV1 wild-type (WT) and knock-out (KO) mice and with administration of a TRPV1 antagonist in mice and rats. Administration of morphine by subcutaneous implantation of morphine pellets elicited both thermal and tactile hypersensitivity in TRPV1 WT mice but not in TRPV1 KO mice. Moreover, oral administration of a TRPV1 antagonist reversed both thermal and tactile hypersensitivity induced by sustained morphine administration in mice and rats. Immunohistochemical analyses indicate that sustained morphine administration modestly increases TRPV1 labeling in the dorsal root ganglia. In addition, sustained morphine increased flinching and plasma extravasation after peripheral stimulation with capsaicin, suggesting an increase in TRPV1 receptor function in the periphery in morphine-treated animals. Collectively, our data indicate that the TRPV1 receptor is an essential peripheral mechanism in expression of morphine-induced hyperalgesia. PERSPECTIVE: Opioid-induced hyperalgesia possibly limits the usefulness of opioids, emphasizing the value of alternative methods of pain control. We demonstrate that TRPV1 channels play an important role in peripheral mechanisms of opioid-induced hyperalgesia. Such information may lead to the discovery of analgesics lacking such adaptations and improving treatment of chronic pain.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774343      PMCID: PMC3385996          DOI: 10.1016/j.jpain.2008.07.004

Source DB:  PubMed          Journal:  J Pain        ISSN: 1526-5900            Impact factor:   5.820


  76 in total

1.  Spinally administered dynorphin A produces long-lasting allodynia: involvement of NMDA but not opioid receptors.

Authors:  T M Laughlin; T W Vanderah; J Lashbrook; M L Nichols; M Ossipov; F Porreca; G L Wilcox
Journal:  Pain       Date:  1997-08       Impact factor: 6.961

Review 2.  World Health Organization guidelines for cancer pain: a reappraisal.

Authors:  S Mercadante; F Fulfaro
Journal:  Ann Oncol       Date:  2005-05       Impact factor: 32.976

3.  AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo[b][1,4] dioxin-6-yl)acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties.

Authors:  Narender R Gavva; Rami Tamir; Yusheng Qu; Lana Klionsky; T J Zhang; David Immke; Judy Wang; Dawn Zhu; Todd W Vanderah; Frank Porreca; Elizabeth M Doherty; Mark H Norman; Kenneth D Wild; Anthony W Bannon; Jean-Claude Louis; James J S Treanor
Journal:  J Pharmacol Exp Ther       Date:  2004-12-22       Impact factor: 4.030

Review 4.  Ion channels gated by heat.

Authors:  P Cesare; A Moriondo; V Vellani; P A McNaughton
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-06       Impact factor: 11.205

Review 5.  Functional aspects and mechanisms of TRPV1 involvement in neurogenic inflammation that leads to thermal hyperalgesia.

Authors:  Rosa Planells-Cases; Nuria Garcìa-Sanz; Cruz Morenilla-Palao; Antonio Ferrer-Montiel
Journal:  Pflugers Arch       Date:  2005-05-21       Impact factor: 3.657

6.  Evidence for spinal dorsal horn hyperexcitability in rats following sustained morphine exposure.

Authors:  Rie Suzuki; Frank Porreca; Anthony H Dickenson
Journal:  Neurosci Lett       Date:  2006-09-07       Impact factor: 3.046

7.  Cholecystokinin in the rostral ventromedial medulla mediates opioid-induced hyperalgesia and antinociceptive tolerance.

Authors:  Jennifer Y Xie; David S Herman; Carl-Olav Stiller; Luis R Gardell; Michael H Ossipov; Josephine Lai; Frank Porreca; Todd W Vanderah
Journal:  J Neurosci       Date:  2005-01-12       Impact factor: 6.167

8.  Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.

Authors:  Shao-Rui Chen; Hui-Lin Pan
Journal:  J Neurophysiol       Date:  2006-02-08       Impact factor: 2.714

9.  NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels.

Authors:  Xuming Zhang; Jiehong Huang; Peter A McNaughton
Journal:  EMBO J       Date:  2005-12-01       Impact factor: 11.598

10.  Role of NK-1 neurotransmission in opioid-induced hyperalgesia.

Authors:  Tamara King; Luis R Gardell; Ruizhong Wang; Anna Vardanyan; Michael H Ossipov; Philip T Malan; Todd W Vanderah; Stephen P Hunt; Victor J Hruby; Josephine Lai; Frank Porreca
Journal:  Pain       Date:  2005-08       Impact factor: 7.926

View more
  21 in total

1.  Opioid Induced Hyperalgesia, a Research Phenomenon or a Clinical Reality? Results of a Canadian Survey.

Authors:  Grisell Vargas-Schaffer; Suzie Paquet; Andrée Neron; Jennifer Cogan
Journal:  J Pers Med       Date:  2020-04-21

Review 2.  The role of mitogen-activated protein kinase (MAPK) in morphine tolerance and dependence.

Authors:  Yong Chen; Claudia Sommer
Journal:  Mol Neurobiol       Date:  2009-05-26       Impact factor: 5.590

Review 3.  The mechanism of μ-opioid receptor (MOR)-TRPV1 crosstalk in TRPV1 activation involves morphine anti-nociception, tolerance and dependence.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Jing Yu; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015-07-15       Impact factor: 2.581

Review 4.  Pathophysiology of medication overuse headache: insights and hypotheses from preclinical studies.

Authors:  Ian D Meng; David Dodick; Michael H Ossipov; Frank Porreca
Journal:  Cephalalgia       Date:  2011-03-28       Impact factor: 6.292

5.  Opioid-induced hypernociception is associated with hyperexcitability and altered tetrodotoxin-resistant Na+ channel function of dorsal root ganglia.

Authors:  Gracious R Ross; Aravind R Gade; William L Dewey; Hamid I Akbarali
Journal:  Am J Physiol Cell Physiol       Date:  2011-12-21       Impact factor: 4.249

6.  Exchange factor directly activated by cAMP-PKCε signalling mediates chronic morphine-induced expression of purine P2X3 receptor in rat dorsal root ganglia.

Authors:  Wenying Wang; Xiaqing Ma; Limin Luo; Min Huang; Jing Dong; Xiaoli Zhang; Wei Jiang; Tao Xu
Journal:  Br J Pharmacol       Date:  2018-04-06       Impact factor: 8.739

7.  Fatty acid amide hydrolase and monoacylglycerol lipase inhibitors produce anti-allodynic effects in mice through distinct cannabinoid receptor mechanisms.

Authors:  Steven G Kinsey; Jonathan Z Long; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pain       Date:  2010-06-16       Impact factor: 5.820

Review 8.  Complications of long-term opioid therapy for management of chronic pain: the paradox of opioid-induced hyperalgesia.

Authors:  D Eric Brush
Journal:  J Med Toxicol       Date:  2012-12

9.  The Complement System Component C5a Produces Thermal Hyperalgesia via Macrophage-to-Nociceptor Signaling That Requires NGF and TRPV1.

Authors:  Leonid P Shutov; Charles A Warwick; Xiaoyu Shi; Aswini Gnanasekaran; Andrew J Shepherd; Durga P Mohapatra; Trent M Woodruff; J David Clark; Yuriy M Usachev
Journal:  J Neurosci       Date:  2016-05-04       Impact factor: 6.167

10.  Exogenous and endogenous opioid-induced pain hypersensitivity in different rat strains.

Authors:  Emilie Laboureyras; Frédéric Aubrun; Maud Monsaingeon; Jean-Benoît Corcuff; Jean-Paul Laulin; Guy Simonnet
Journal:  Pain Res Manag       Date:  2014-05-16       Impact factor: 3.037

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.